

## Revised Agenda

New Jersey Drinking Water Quality Institute (DWQI)

Thursday June 30, 2016, 1 pm

[USGS NJ Water Science Center](#)

3450 Princeton Pike, Suite 110

Lawrenceville, NJ 08648

Phone: 609-771-3900

The meeting is open to the public. All attendees will be asked to sign in and provide contact information.


	<u>Time</u>
1. <b>DWQI Chair:</b> Welcoming remarks and introduction of the DWQI members present, new member [ <b>Dr. Daniel Salvito</b> ] and member stepping down off [ <b>Laura Cummings, PE</b> ] the DWQI (Keith Cooper)	10 minutes
2. <b>Review of October 28, 2015 Minutes</b>	5 Minutes
3. <b>1,2,3-Trichloropropane:</b> <ul style="list-style-type: none"><li>• Overview of Next Steps (Keith Cooper)</li><li>• Report from Treatment Subcommittee on review of 2009 DWQI MCL recommendation (Laura Cummings)</li></ul>	20 minutes
4. <b>DWQI Questions</b>	10 minutes
5. <b>Public Comments</b>	5 minutes/comment
6. <b>Polyfluorinated alkyl substances (PFASs) :</b>	20 minutes
7. <b>Public Comments</b>	<b>15 Minutes</b>
8. <b>Adjourn Public Meeting</b>	
9. <b>Full DWQI non-public meeting</b>	

# **A Short Update on Perfluorinated Alkyl Substances (PFAS)**

**Keith R. Cooper**

**New Jersey Drinking Water Quality Institute  
June 30, 2016**

# PUBLIC PARTICIPATION IN MCL DEVELOPMENT PROCESS



# Overview of DWQI PFOA Health Effects Approach

- Health-based goals from 1983 A-280 Amendments to NJ Safe Drinking Water Act
  - Non-cancer: No adverse physiological effects from ingestion
  - Cancer: One in one million risk from lifetime exposure
- Risk assessment approach – based on USEPA guidance
- Extensive literature search – more than 2,000 publications
- Focused on key human and animal effects
- Epidemiological data
  - Limitations preclude use as primary basis for Health-based MCL
  - Justify concern about substantial ↑ in blood levels from drinking water
  - Support public health protective approach based on animal data
- Toxicological data - evaluated non-cancer and cancer effects
- Mode of action and human relevance – thorough evaluation
- Dose-response modeling
  - Benchmark dose modeling of non-cancer and cancer effects
  - Considers greater persistence in humans than animals


# Overview of Process and Current Status

- 2007:** NJDEP chronic PFOA drinking water guidance of 40 ng/L. Basis was published (Post et al., 2009).
- 2009:** USEPA short term Provisional Health Advisories for PFOA (400 ng/L) and PFOA (200 ng/L).
- 2009-10:** DWQI voted to develop MCL for PFOA. Detailed evaluation subsequently performed by Health Effects (HE) Subcommittee.
- 2012:** Review of PFOA as an emerging drinking water contaminant by current and former HE Subcommittee members (Post et al., 2012).
- 2014:** NJDEP Commissioner Martin asked DWQI to recommend MCLs for PFNA, PFOA, and PFOS.
- 2015:** DWQI recommended PFNA MCL of 13 ng/L.
- May/2016:** USEPA finalized Lifetime Health Advisories for PFOA, PFOS, and total of PFOA + PFOS of 70 ng/L.
- June-July/2016:** HE Subcommittee finalizes Public Review Draft of Health-based MCL Support Document for PFOA and the Treatment and Analytical .


# PFOA is a Persistent Bioaccumulative and Toxic (PBT) Drinking Water Contaminant

- Different from most other PBT compounds
  - Water soluble - important as drinking water contaminant
- Persists in environment and human body
  - Remains in the body for many years after exposure ends
- Bioaccumulates from drinking water to humans
  - Ratio greater than 100:1
  - Low concentrations → several-fold ↑ in blood levels (**Central Compartment actual internal dose**)
- Infants' blood levels much higher from same exposures
  - Transferred to breast milk in mother
  - In formula prepared with contaminated water
  - Fluid consumption much higher on body weight basis
  - Sensitive subpopulation for developmental effects

# Relatively Low Concentrations of PFOA in Drinking Water Substantially Increase PFOA in Blood Serum



## Increases in Blood Serum PFOA are Greater in Infants Considered as a Sensitive Stage of Human Development



Verner et al., 2016



## Next Steps for the DWQI for 1,2,3-Trichloropropane & PFASs

- The 1,2,3-Trichloropropane **Public Review Draft will be posted for comment in the next few weeks** based on the reports from each of the committees and public comment along with any presentations.
- At the next meeting the DWQI will discuss all of the comments and submit a revised document based on consideration of the submitted comments to Commissioner Martin for further policy and cost review for promulgating an MCL.

## Next Steps for the DWQI for 1,2,3-Trichloropropane & PFASs

- PFOS is likely to be the next compound to be evaluated based on Commissioner Martin's March 2014 letter request.
- The DWQI will convene into a closed session where each of the Chairs of the committees will present their individual committee conclusions concerning PFOA to the full DWQI members and a discussion on the committee findings as they relate to the final recommendations and posting of the Public Review Draft.

# PUBLIC PARTICIPATION IN MCL DEVELOPMENT PROCESS

